Inclusion Criteria:  understand and voluntarily sign a written informed consent; Age: from 18 to 75 years, No restriction on gender; Patients must have primary hepatocellular carcinoma; Clinical stage: stage Ia~III a; Child-pugh score ≤7; HLA-A02 and consistent with ≥1 NeoAg or ≥2 aeTSA peptide bank; ECOG PS score: 0~2; Laboratory values as follow: White blood cell count ≥ 3×109/L; Neutrophils: more than 1.5 × 109/L; Hemoglobin: more than 85g/L; Platelets: more than 5 × 1010/L; Total bilirubin:≤2 × ULN; Serum AST(GOT) and ALT(GPT)≤2.5 × ULN; Albumin ≥3.0 g/dL (30 g/L); Serum creatinine: less than 1.5 × ULN; Coagulation time was basically normal, PT extension ≤4s; No serious cardiopulmonary disease; Blood collection body weight: male > 50 kg, female > 45 kg; No obvious hereditary diseases; Expected survival: more than 6 months;  Exclusion Criteria:  Patient has known distant organ metastasis; Suffer from lymphoma or leukemia or MDS (myelodysplastic syndrome), etc.; Woman be pregnant or lactating; Suffer from mental or neurological diseases that are resistant to control; The investigator judges that it is not suitable to participate in this clinical research (such as poor compliance, etc.); Patients infected with human immunodeficiency virus (commonly known as AIDS) or Treponema pallidum (commonly known as syphilis); Patients with a history of other malignant tumors in the past 5 years; Organ transplantation or Myelosuppression; History of drug abuse or alcohol abuse;